A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation

A phase I study of nolatrexed, administered as a continuous 5 day intravenous infusion every 28 days, has been undertaken for children with advanced malignancy. 16 patients were treated at 3 dose levels; 420, 640 and 768 mg/m(2) 24 h(−1). 8 patients were evaluable for toxicity. In the 6 patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Estlin, E J, Pinkerton, C R, Lewis, I J, Lashford, L, McDowell, H, Morland, B, Kohler, J, Newell, D R, Boddy, A V, Taylor, G A, Price, L, Ablett, S, Hobson, R, Pitsiladis, M, Brampton, M, Clendeninn, N, Johnston, A, Pearson, A D J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363615/
https://www.ncbi.nlm.nih.gov/pubmed/11139306
http://dx.doi.org/10.1054/bjoc.2000.1569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363615/
https://www.ncbi.nlm.nih.gov/pubmed/11139306
http://dx.doi.org/10.1054/bjoc.2000.1569

Ejemplares similares